Document is current
Any future updates will be listed below
-
Authors
Galand, Claire
Venkatraman, Vignesh
Marques, Marilyn
Strauss, James
Carvajal, Richard
Lim, Min
Morin, Benjamin
Ignatovich, Olga
Findeis, Mark
Underwood, Dennis
Dijk, Marc Van
Shapiro, Irina
Ohanjanian, Lernik
Wijatyk, Anna
Wilson, Nicholas
Buell, Jennifer
Chand, Dhan
Savitsky, David
Tolcher, Anthony
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04121676 at ClinicalTrials.govDocuments that mention this clinical trial
377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects
https://doi.org/10.1136/jitc-2020-sitc2020.0377
A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.2524
- License Information
